Эффективность применения эфира икозапента у лиц с гипертриглицеридемией: результаты рандомизированного исследования REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl Intervention Trial)

Авторы:
  • Редакция
Журнал: Доказательная кардиология (электронная версия, архив до 2019). 2018;11(3): 10-16
Просмотрено: 674 Скачано: 107
Источник: Bhatt D.L., Steg P.G., Miller M., et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2018 Nov 10. https://doi.org/10.1056/NEJMoa1812792. [Epub ahead of print] У лиц с повышенной концентрацией триглицеридов в крови, несмотря на прием статинов, риск развития осложнений, обусловленных ишемией, включая смерть от осложнений сердечно-сосудистых заболеваний, при приеме эфира икозапента по 2 г 2 раза в день был статистически значимо меньше, чем при приеме плацебо.

КАК ЦИТИРОВАТЬ:

Редакция Эффективность применения эфира икозапента у лиц с гипертриглицеридемией: результаты рандомизированного исследования REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl Intervention Trial). Доказательная кардиология (электронная версия, архив до 2019). 2018;11(3):10-16.

Список литературы:

  1. Bhatt D.L., Eagle K.A., Ohman E.M., et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 2010;304:1350—1357.
  2. Nambi V., Bhatt D.L. Primary prevention of atherosclerosis: time to take a selfie? J Am Coll Cardiol 2017;70:2992—2994.
  3. Vaduganathan M., Venkataramani A.S., Bhatt D.L. Moving toward global primordial prevention in cardiovascular disease: the heart of the matter. J Am Coll Cardiol 2015;66:1535—1537.
  4. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495—504.
  5. Libby P. Triglycerides on the rise: should we swap seats on the seesaw? Eur Heart J 2015;36:774—776.
  6. Klempfner R., Erez A., Sagit B.Z., et al. Elevated triglyceride level is independent- ly associated with increased all-cause mortality in patients with established coronary heart disease: twenty-two-year follow-up of the Bezafibrate Infarction Prevention Study and Registry. Circ Cardiovasc Qual Outcomes 2016;9:100—108.
  7. Nichols G.A., Philip S., Reynolds K., et al. Increased cardiovascular risk in hypertriglyceridemic patients with statin-controlled LDL cholesterol. J Clin Endocrinol Metab 2018;103:3019—3027.
  8. Nichols G.A., Philip S., Reynolds K., et al. Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol. Diabetes Obes Metab 2018 September 17 (Epub ahead of print).
  9. Toth P.P., Granowitz C., Hull M., et al. High triglycerides are associated with increased cardiovascular events, medical costs, and resource use: a real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. J Am Heart Assoc 2018;7(15):e008740.
  10. Ganda O.P., Bhatt D.L., Mason R.P., et al. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol 2018;72:330—343.
  11. The ORIGIN Trial Investigators. n−3 Fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012;367:309—318.
  12. The ASCEND Study Collaborative Group. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med 2018;379:1540—1550.
  13. Aung T., Halsey J., Kromhout D., et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals. JAMA Cardiol 2018;3:225—234.
  14. Yokoyama M., Origasa H., Matsuzaki M., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090—1098.
  15. Bays H.E., Ballantyne C.M., Kastelein J.J., et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multicenter, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol 2011;108:682—690.
  16. Ballantyne C.M., Bays H.E., Kastelein J.J., et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol 2012;110:984—992.
  17. Bays H.E., Ballantyne C.M., Braeckman R.A., et al. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am J Cardiovasc Drugs 2013;13:37—46.
  18. Nelson J.R., Wani O., May H.T., Budoff M. Potential benefits of eicosapentaenoic acid on atherosclerotic plaques. Vascul Pharmacol 2017;91:1—9.
  19. Mason R.P., Jacob R.F., Shrivastava S., et al. Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes. Biochim Biophys Acta 2016;1858:3131—3140.
  20. Sherratt S.C.R., Mason R.P. Eicosapentaenoic acid and docosahexaenoic acid have distinct membrane locations and lipid interactions as determined by X-ray diffraction. Chem Phys Lipids 2018;212:73—79.
  21. Itakura H., Yokoyama M., Matsuzaki M., et al. Relationship between plasma fatty acid composition and coronary artery disease. J Atheroscler Thromb 2011;18:99—107.
  22. Bays H.E., Ballantyne C.M., Doyle R.T. Jr, et al. Icosapent ethyl: eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies. Prostaglandins Other Lipid Mediat 2016;125:57—64.
  23. Chang C.H., Tseng P.T., Chen N.Y., et al. Safety and tolerability of prescription omega-3 fatty acids: a systematic review and meta-analysis of randomized controlled trials. Prostaglandins Leukot Essent Fatty Acids 2018;129:1—12.
  24. Nicholls S.J., Lincoff A.M., Bash D., et al. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: rationale and design of the STRENGTH trial. Clin Cardiol 2018;41:1281—1288.
  25. Bhatt D.L., Hulot J.S., Moliterno D.J., Harrington R.A. Antiplatelet and anticoagulation therapy for acute coronary syndromes. Circ Res 2014;114:1929—1943.
  26. Doi M., Nosaka K., Miyoshi T., et al. Early eicosapentaenoic acid treatment after percutaneous coronary intervention reduces acute inflammatory responses and ventricular arrhythmias in patients with acute myocardial infarction: a randomized, controlled study. Int J Cardiol 2014;176:577—582.
  27. Watanabe T., Ando K., Daidoji H., et al. A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins. J Cardiol 2017;70:537—544.
  28. Borow K.M., Nelson J.R., Mason R.P. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Atherosclerosis 2015;242:357—366.
  29. Ridker P.M., Everett B.M., Thuren T., et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017;377:1119—1131.
  30. Verma S., Leiter L.A., Bhatt D.L. CANTOS ushers in a new calculus of inflammasome targeting for vascular protection — and maybe more. Cell Metab 2017;26:703—705.
  31. Hong K.N., Fuster V., Rosenson R.S., et al. How low to go with glucose, cholesterol, and blood pres- sure in primary prevention of CVD. J Am Coll Cardiol 2017;70:2171—2185.
  32. Budoff M., Brent Muhlestein J., Le V.T., et al. Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200—499 mg/dL) on statin therapy: rationale and design of the EVAPORATE study. Clin Cardiol 2018;41:13—19.
  33. Cannon C.P., Blazing M.A., Giugliano R.P., et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387—2397.
  34. Schwartz G.G., Steg P.G., Szarek M., et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018;379:2097—2107.